To evaluate safety and efficacy of GS-9857 plus sofosbuvir/velpatasvir for 12 weeks in treatment experienced genotype 1-6 HCV infected patients with and Without Cirrhosis.
Latest Information Update: 06 Jan 2017
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary) ; Voxilaprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 06 Jan 2017 New trial record